Back to today’s briefing

Story perspectives

Foundayo Rx Jump, Analyst Skeptical; Novo’s Wegovy Explodes

4/24/2026

39 5 Full Breakdown

Summary

Story summary

Foundayo was prescribed 3,707 times in its second week, up from 1,390 in the debut week.
Novo Nordisk’s oral obesity drug Wegovy filled 18,410 prescriptions in its second week, up from 3,071 in the first week.
RBC Capital Markets analyst Trung Huynh said Foundayo’s early uptake is likely to be viewed negatively.
Eli Lilly shares fell 1.5% before the bell, contrasting with a 2% rise for Novo Nordisk.

1 of 1

Story summary

Foundayo was prescribed 3,707 times in its second week, up from 1,390 in the debut week.
Novo Nordisk’s oral obesity drug Wegovy filled 18,410 prescriptions in its second week, up from 3,071 in the first week.
RBC Capital Markets analyst Trung Huynh said Foundayo’s early uptake is likely to be viewed negatively.
Eli Lilly shares fell 1.5% before the bell, contrasting with a 2% rise for Novo Nordisk.